71787 Clofarabine - AK Scientific
 
 
Loading Please Wait...
  Catalog ID # 71787
Clofarabine
, 98%
 
(2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol
2-chloro-2'-arabino-fluoro-2'-deoxyadenosine
Clolar
Evoltra




IDENTITY
CAS Registry #:[123318-82-1]
MDL Number:MFCD00871077
MF:C10H11ClFN5O3
MW:303.68
SPECIFICATIONS & PROPERTIES
Purity:98%
Physical Form:White powder
Melting Point:230-233°C
Long-Term Storage:Store long-term at 2-8°C
Shipping:Normal Temperature
Note:Manual review is required before order is released.

BIOLOGICAL INFO
Solubility:DMSO: 61mg/mL; H2O: <1mg/mL; EtOH: <1mg/mL
Application(s):Inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase
Form:Free Base

REVIEW

 Clofarabine is metabolized intracellularly to the active 5'-monophosphate metabolite by deoxycytidine kinase and 5'-triphosphate metabolite by mono- and di-phospho-kinases. This metabolite inhibits DNA synthesis through an inhibitory action on ribonucleotide reductase, and by terminating DNA chain elongation and inhibiting repair through competitive inhibition of DNA polymerases. This leads to the depletion of the intracellular deoxynucleotide triphosphate pool and the self-potentiation of clofarabine triphosphate incorporation into DNA, thereby intensifying the effectiveness of DNA synthesis inhibition. The affinity of clofarabine triphosphate for these enzymes is similar to or greater than that of deoxyadenosine triphosphate. In preclinical models, clofarabine has demonstrated the ability to inhibit DNA repair by incorporation into the DNA chain during the repair process. Clofarabine 5'-triphosphate also disrupts the integrity of mitochondrial membrane, leading to the release of the pro-apoptotic mitochondrial proteins, cytochrome C and apoptosis-inducing factor, leading to programmed cell death.

REFERENCES
[1]Pession A, Masetti R, Kleinschmidt K, Martoni A: Use of clofarabine for acute childhood leukemia. Biologics. 2010 Jun 24;4:111-8.
[2] Harned TM, Gaynon PS: Treating refractory leukemias in childhood, role of clofarabine. Ther Clin Risk Manag. 2008 Apr;4(2):327-36.
[3] Lech-Maranda E, Korycka A, Robak T: Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity. Mini Rev Med Chem. 2009 Jun;9(7):805-12.
[4] Larson ML, Venugopal P: Clofarabine: a new treatment option for patients with acute myeloid leukemia. Expert Opin Pharmacother. 2009 Jun;10(8):1353-7.

Risk Description(s)
R36/37/38:Irritating to eyes, respiratory system and skin

Safety Description(s)
S24/25:Avoid contact with skin and eyes.



Pricing (not showing? please refresh your web browser)

RELATED PRODUCTS
69997Cladribine
71787Clofarabine

CATEGORIES

 APIs and Bioactives > Chemotherapeutics
 Nucleobases > Nucleosides

USEFUL LINKS

  PubChem